SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Passive Stake in Mustang Bio, Inc.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a 4.99% beneficial ownership stake in Mustang Bio, Inc.'s common stock as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") beneficially own 129,213 shares of Mustang Bio, Inc. common stock.
• This ownership represents 4.99% of the company's outstanding common stock.
• The Reporting Persons hold shared voting power and shared dispositive power over all 129,213 shares.
• The filing is an Amendment No. 1 to a previous Schedule 13G, indicating an update to their beneficial ownership.
• The shares were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing the control of Mustang Bio, Inc.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing indicates a significant, albeit passive, stake by an investment firm, which can be seen as a vote of confidence. However, it's an amendment and just under 5%, so the full context of the change isn't provided, preventing a stronger positive sentiment.

Positives

• A notable investment firm, Armistice Capital, holds a significant stake, potentially indicating confidence in Mustang Bio, Inc.'s long-term prospects.
• The filing explicitly states the ownership is for passive investment purposes, not for control, which can alleviate concerns about potential activist investor actions.

Negatives

• The beneficial ownership percentage of 4.99% is just below the 5% threshold, which might suggest a strategic decision to avoid the more stringent reporting requirements of a Schedule 13D, or it could reflect a reduction from a previously higher stake (as this is an amendment).

Future Outlook

The document is an ownership disclosure and does not contain any forward-looking statements or guidance regarding Mustang Bio, Inc.'s future performance, strategic direction, or financial outlook.

Industry Context

This Schedule 13G filing reflects a passive investment by Armistice Capital, LLC and Steven Boyd in Mustang Bio, Inc., a biotechnology company. Such filings are standard for institutional investors managing portfolios and typically do not provide insights into broader industry trends, though they can signal investor interest in specific companies within the biotech sector.

Related Party Transactions

• Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by an investment firm may provide some level of confidence or insight into institutional interest in the company.

Next Steps

• The document does not specify any future actions, events, or milestones for Mustang Bio, Inc. or the reporting persons beyond the ongoing passive investment.

Key Dates

Keywords

Mustang Bio Inc., MBIO, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management